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Liposomes have a wide array of uses that have been continuously expanded and improved upon since ﬁrst being observed to self-
assemble into vesicular structures. These arrangements can be found in many shapes and sizes depending on lipid composition.
Liposomes are often used to deliver a molecular cargo such as DNA for therapeutic beneﬁt. The lipids used to form such lipoplexes
canbecationic,anionic,neutral,oramixturethereof.Hereinphysicalpackingparametersandspeciﬁclipidsusedforgenedelivery
will be discussed, with lipids classiﬁed according to overall charge.
1.Introduction
Liposomes are vesicular structures that can form via the
accumulation of lipids interacting with one another in an
energetically favorable manner. Depending upon the struc-
ture and the composition of the bulk solution, liposomes
can separate hydrophobic or hydrophilic molecules from the
solution. These vesicles are not rigid formations but rather
areﬂuidentitiesthatareversatilesupramolecularassemblies.
Because they have dynamic properties and are relatively
easy to manipulate, liposomes have been used widely in the
analytical sciences as well as for drug and gene delivery.
Since their ﬁrst published use in 1965 [1, 2], the value and
practicality of liposome functions have been recognized and
continually improved upon.
The advances that brought about liposome-derived tech-
nologies have been recognized as some of the cornerstones of
bionanotechnology [3]. The unique advantages imparted by
lipidvesiclesaretheirdiverserangeofmorphologies,compo-
sitions, abilities to envelope and protect many types of ther-
apeutic biomolecules, lack of immunogenic response, low
cost,andtheir diﬀerential release characteristics[4–6].These
characteristics have led to applications in chemical and bio-
chemical analytics, cosmetics, food technologies, and drug
and gene delivery [7, 8]. There are numerous lipid formula-
tions for each of these applications. However, this review will
focus primarily on the use of liposomes for gene delivery.
2.Characteristics
Liposomes are generally formed by the self-assembly of dis-
solved lipid molecules, each of which contains a hydrophilic
head group and hydrophobic tails. These lipids take on
associations which yield entropically favorable states of low
free energy, in some cases forming bimolecular lipid leaﬂets
(Figure 1). Such leaﬂets are characterized by hydrophobic
hydrocarbon tails facing each other and hydrophilic head
groups facing outward to associate with aqueous solution
[9]. At this point, the bilayer formation is still energetically
unfavorable because the hydrophobic parts of the molecules
are still in contact with water, a problem that is overcome
through curvature of the forming bilayer membrane upon
itself to form a vesicle with closed edges [10]( Figure 1).
This free-energy-driven self-assembly is stable and has
been exploited as a powerful mechanism for engineering
liposomes speciﬁcally to the needs of a given system [11].
Lipid molecules used in liposomes are conserved entities
with a head group and hydrophobic hydrocarbon tails
connected via a backbone linker such as glycerol [12].
Cationic lipids commonly attain a positive charge through
one or more amines present in the polar head group. The
presenceofpositively chargedaminesfacilitatesbinding with
anions such as those found in DNA. The liposome thus
formedisaresultofenergeticcontributionsbyVanderWaals
forces and electrostatic binding to the DNA which partially2 Journal of Drug Delivery
Figure 1: Certain amphipathic lipid molecules in aqueous solution spontaneously form leaﬂets, then bilayer membranes, and eventually
liposomes.
dictates liposome shapes [13]. Because of the polyanionic
nature of DNA, cationic (and neutral) lipids are typically
used for gene delivery, while the use of anionic liposomes
has been fairly restricted to the delivery of other therapeutic
macromolecules [14].
Liposomes can exhibit a range of sizes and morphologies
upon the assemblyof pure lipids or lipid mixtures suspended
in an aqueous medium [2]. A common morphology which
is analogous to the eukaryotic cellular membrane is the unil-
amellarvesicle.Thisvesicleischaracterizedbyasinglebilayer
membrane which encapsulates an internal aqueous solution,
thus separating it from the external (bulk) solution [15].
Both cationic amine head groups and anionic phospholipid
head groups can form these single-walled vesicles. Vesicle
sizes fall into the nanometer to micrometer range: small
unilamellar vesicles are 20–200nm, large unilamellar vesicles
are 200nm–1μm, and giant unilamellar vesicles are larger
than 1μm[ 2].
Giant vesicles also include other morphologies such
as multilamellar, which consists of multiple concentric
bilayers, oligolamellar, which consists of only two concentric
bilayers, and multivesicular, which consists of multiple
smaller unilamellar vesicles inside of one giant one. With the
exceptionofmultilamellarvesicles,theseothermorphologies
are diﬃcult to obtain without highly controlled processes for
formation [2]. Giant vesicles also deserve special attention
because their sizes are large, ranging from 1μmt om o r e
than 100μm[ 2]. These large vesicles are studied and well
characterized, partially due to the ease of observation via
optical microscopy [10].
During the compaction of polynucleotides into liposo-
mal assemblies, a number of structures have been known
to appear [5, 6, 16–19]. Each structure is formed in the
most energetically favorable conformation based upon char-
acteristics of the speciﬁc lipids used in the system [13]. A
dependent term known as the structure-packing parameter
can be used to suggest what shape the amphiphile will
take, depending on the ratio of size variables. The packing
parameter is deﬁned as
P =
v
alc
,( 1 )
where v: the volume of the hydrocarbon portion, a: the
eﬀective area of the head group, and lc: the length of the lipid
tail.
This correlation predicts a range of structures according
to the following conditions [13, 20]( Figure 2):
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1
3
−→ spherical micelle,
1
3
≤ P<
1
2
−→ cylindrical micelle,
1
2
≤ P<1 −→ ﬂexible bilayers,vesicles,
P = 1 −→ planar bilayers,
P>1 −→ inverted micelles,

hexagonal (HII)phase

.
(2)
3. CationicLipids
A solution of cationic lipids, often formed with neutral hel-
per lipids, can be mixed with DNA to form a positively char-
ged complex termed a lipoplex [21]. Well-characterized and
widely used commercial reagents for cationic lipid transfec-
tion include N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethy-
lammonium chloride(DOTMA) [22], [1,2-bis(oleoyloxy)-
3-(trimethylammonio)propane] (DOTAP) [23], 3β[N-(N ,
N -dimethylaminoethane)-carbamoyl] cholesterol (DC-
Chol) [24], and dioctadecylamidoglycylspermine (DOGS)
[25]. Dioleoylphosphatidylethanolamine (DOPE), a neutral
lipid, is often used in conjunction with cationic lipids
because of its membrane destabilizing eﬀects at low pH,
which aide in endolysosomal escape [26].
Many cationic lipid compounds have been formulated
since the advent of DOTMA [27–31]. Each lipid has diﬀerent
structural aspects, such as head group size and hydrocarbon
tail length. These aspects confer distinct characteristics to the
lipid/DNA complex, which in turn aﬀect association with
and uptake into the cell. However, the basic structure of
cationic lipids mimics the chemical and physical attributes of
biological lipids [32]. The positive charge on the head group
facilitatesspontaneouselectrostaticinteractionwithDNA,as
well as binding of the resulting lipoplexes to the negativelyJournal of Drug Delivery 3
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Figure 2: Structures predicted by the packing parameter P.
charged components of the cell membrane prior to cellular
uptake [33, 34]. The use of a cation is a recurring theme
for virtually all chemically mediated gene delivery vectors,
including polymers, lipids, and nondegradable nanoparti-
cles.
Between 8–18 carbons commonly comprise the hydro-
carbon tails of lipids used for gene delivery. The tails are
typically saturated, but a single double bond is occasionally
seen. The combination of hydrocarbon chains in a lipid
mixture can be symmetric or asymmetric. It has been shown
that certain asymmetric lipid mixtures with both shorter
saturated carbon chains and long unsaturated carbon chains
produce relatively high transfection eﬃciencies as compared
to mixed formulations of symmetric cationic lipids [35].
Hydrophobic tails are not the only liposomal features
that play a role in eﬀective gene delivery—ionizable head
groups are also involved. Some examples are the multivalent
cationic lipids DOSPA and DOGS (covered in Section 3.2);
both of which have a functionalized spermine head group
that confers the ability to act as a buﬀe r ,s u c ha si nt h e
case where there is an inﬂux of protons into a maturing
endosome/endolysosome [36]. Such buﬀering could extend
the amount of time needed to activate acid hydrolases
and could explain why some multivalent cationic lipids4 Journal of Drug Delivery
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Figure 3: The structure of DOTMA.
can exhibit higher transfection eﬃciencies versus their
monovalent counterparts [25, 37].
3.1. Monovalent Cationic Lipids
3.1.1. DOTMA (see Figure 3). N-[1-(2,3-dioleyloxy) prop-
yl]-N,N,N-trimethylammonium chloride, or DOTMA, was
one of the ﬁrst synthesized and commercially available
cationic lipids used for gene delivery. Its structure consists
of 2 unsaturated oleoyl chains (C18:Δ9), bound by an
ether bond to the three-carbon skeleton of a glycerol, with
a quaternary amine as the cationic head group [22]. As
compared to other methods of gene transfer used in the
late 1980s, DOTMA proved to facilitate up to 100-fold
more eﬃcient gene delivery than the use of DEAE-dextran
coprecipitation or calcium phosphate [22]. The ability to
entrap DNA or RNA in a liposome in a relatively simple
fashion, with eﬀective gene delivery to cells, signiﬁcantly
inﬂuenced and improved the potential of nonviral agents for
gene therapy [22, 38]. Based upon the use of comparative
protein expression assays such as luciferase, β-galactosidase,
or chloramphenicol acetyltransferase, initial success of in
vitrotransfectionofmultiplecelllineswithDOTMAsparked
a number of attempts to improve the lipid formulation
a n dr e s u l t e di nt h ec r e a t i o no fm a n ye ﬀective formula-
tions including such notable lipids as DOTAP [23] (see
Section 3.1.2) and DC-Chol [24]( Section 3.1.3).
Commercialization of DOTMA as Lipofectin involved
its coupling with DOPE (Section 4.1)i na1 / 1r a t i od u e
to the ability of DOPE to increase transfection eﬃciencies.
Once commercialized, improvements in Lipofectin were
desired, motivating others to add functional groups to
the DOTMA. Many alterations made in the four major
moieties of DOTMA (head group, linker, linkage bonds,
and hydrocarbon chains) have reﬂected widespread eﬀorts to
reduce toxicity and increase transfection eﬃciencies [23, 39].
These studies have suggested, however, that cytotoxicities
associated with the formulated monovalent lipids were
dependent on plated cell density. Plate densities of 25%–
35%, treated with cationic lipoplexes, yielded roughly half
the amount of cell protein per plate versus controls. Near-
conﬂuent cell monolayers exhibited very little evidence of
cytotoxicity. These ﬁndings supported a need for manip-
ulations in the structural aspects of the lipids for lowered
cytotoxicity in subconﬂuent populations [23]. Felgner et al.
[40] also experimented with novel lipid formulations by
altering DOTMA to obtain a more robust understanding of
the mechanism of biological action. The structural changes
included diﬀerent combinations of side chains and alkyl
attachments to the head groups, as well as the replacement
of a methyl group on the quaternary amine of DOTMA
with a hydroxyl. Their report suggested that compounds
with such a hydroxyl modiﬁcation display improved protein
expression after transfection by two- to three-fold over
those observed following DOTMA-mediated transfections.
Stabilization of the bilayer vesicles was purported to occur
as a result of the hydroxyl group remaining in contact with
the aqueous layer surrounding the liposome. Compounds
lacking this moiety were hypothesized to become entrenched
in the aliphatic region, thus destabilizing the membrane. It
was also indicated that aliphatic chain length had a large
eﬀect on the eﬃcacy of lipid vectors. As the lengths of the
saturated chains were increased in the DOTMA analogs,
transfection eﬃciencies decreased. This was thought to be
due to increased bilayer stiﬀness, which may have prevented
eﬃcient ﬂuid interactions with the endosomal membrane to
thus hamper the release of the liposomes or plasmid DNA
from the endosomal compartments.
3.1.2. DOTAP (see Figure 4). [1,2-bis(oleoyloxy)-3-(trime-
thylammonio)propane], or DOTAP, was ﬁrst synthesized by
Leventis and Silvius in 1990 [23]. The molecule consists of a
quaternaryamineheadgroupcoupledtoaglycerolbackbone
with two oleoyl chains. The only diﬀerences between this
molecule and DOTMA are that ester bonds link the chains
to the backbone rather than ether bonds. It was originally
hypothesized that ester bonds, which are hydrolysable, could
render the lipid biodegradable and reduce cytotoxicity. This
study showed that the transfection activities and levels of
cytotoxicity associated with DOTAP/DOPE formulations
are not statistically diﬀerent from those associated with
DOTMA/DOPE composites. Notably, this type of mono-
valent lipids also showed little to no cytotoxic eﬀect on
near-conﬂuent cell monolayers, in addition to exhibiting
the same lipoplex sensitivity at 25%–35% cell conﬂuence as
mentioned in Section 3.1.1 [23].Journal of Drug Delivery 5
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The use of 100% DOTAP for gene delivery is ineﬃcient
due to the density of positive charges on the liposome
surface, which possibly prevents counter ion exchange [41].
DOTAP is completely protonated at pH 7.4 (which is not
the case for all other cationic lipids) [41], so it is possible
that more energy is required to separate the DNA from the
lipoplex for successful transfection [42]. Thus, for DOTAP
to be more eﬀective in gene delivery, it should be combined
with a helper lipid, as seems to be the case for most cationic
lipid formulations.
High temperature and long incubation times have
been used to create lipoplexes that exhibit resistance to
serum interaction [43]. Interestingly, this approach was
only observed to aﬀect monovalent cationic lipids such as
DOTMA, DOTAP, or DC-Chol, as opposed to multivalent
cationic lipids. The speciﬁc reasons for this phenomenon
remain unclear. In fact, the speciﬁc mechanism behind
serum inactivation of lipoplexes in general is as yet unex-
plained. Several hypotheses have been oﬀered as to the
mechanism, including the prevention of lipoplex binding to
cell membranes by serum proteins [34, 43], the prevention
of structural complex maturation by serum proteins binding
to cationic charges on the lipoplexes [43], and the disparity
of endocytosis pathways—which have varying kinetics—
that are used for lipoplex endocytosis, with the method of
endocytosis being regulated by the size of the lipoplexes or
aggregates of lipoplexes plus serum proteins [34, 44].
3.1.3. DC-Chol (see Figure 5). 3β[N-(N’,N’-dimethylami-
noethane)-carbamoyl]cholesterol, or DC-Chol, was ﬁrst
synthesized by Gao and Huang in 1991 [24]. DC-Chol
contains a cholesterol moiety attached by an ester bond
to a hydrolysable dimethylethylenediamine. Cholesterol was
reportedly chosen for its biocompatibility and the stability it
imparts to lipid membranes, an idea which was supported
by observed transfection activity of up to two- to four-fold
greater chloramphenicol acetyltransferase expression (CAT
assay). Additionally, DC-Chol was found to have a four-fold
reduction in cytotoxicity versus Lipofectin in some cell lines
[24].
Incontrasttocationicliposomescontainingfullycharged
quaternary amines (e.g. DOTMA and DOTAP), DC-Chol, in
a 1:1 lipid ratio with DOPE, contains a tertiary amine that is
charged on 50% of the liposome surface at pH 7.4 [45]. This
feature is thought to reduce the aggregation of lipoplexes
leading to higher transgene expression [46]. The reduction
in overall lipoplex charge can also aid in DNA dissociation
during gene delivery [41], which has been proven to be
necessary for successful transfection [42].
3.2. Multivalent Cationic Lipids
3.2.1. DOSPA (see Figure 6). 2,3-dioleyloxy-N-[2(spermi-
necarboxamido)ethyl]-N,N-dimethyl-l-propanaminium tri-
ﬂuoroacetate, or DOSPA, is another cationic lipid synthe-
sized as a derivative of DOTMA. The structure is similar
to DOTMA except for a spermine group which is bound
via a peptide bond to the hydrophobic chains. This cationic
lipid, used with the neutral helper lipid DOPE at a 3:1
ratio, is commercially available as the transfection reagent
Lipofectamine. In general, the addition of the spermine
functional group allows for a more eﬃcient packing of DNA
in terms of liposome size. The eﬃcient condensation is
possibly due to the many ammonium groups in spermine.
It has been shown that spermine can interact via hydrogen
bonds with the bases of DNA in such a way as to be attracted
on one strand and wind around the major groove to interact
with complementary bases of the opposite strand [47].
3.2.2.DOGS(seeFigure 7). Di-octadecyl-amido-glycyl-sper-
mine, or DOGS, has a structure similar to DOSPA; both6 Journal of Drug Delivery
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molecules have a multivalent spermine head group and two
18-carbon alkyl chains. However, the chains in DOGS are
saturated, are linked to the head group through a peptide
bond, and lack a quaternary amine. DOGS is commercially
available under the name Transfectam. This lipid has been
used to transfect many cell lines, with transgene expression
levels more than 10-fold greater than those seen following
calcium phosphate transfections [25]. In addition, Behr et al.
showed that not only was DOGS very eﬀective in delivering
the CAT reporter plasmid, but it was also associated with no
noticeable cytotoxicity [25].
Much like the multivalent cationic lipid DOSPA, DOGS
is very eﬃcient at binding and packing DNA, a result of
the spermine head group that so closely associates with
DNA [25]. Characterization of the head group of DOGS
was determined to facilitate not only eﬃcient condensation
of DNA but also buﬀering of the endosomal compartment,
which was thought to protect the delivered DNA from
degradation by pH-sensitive nucleases [36]. DOGS is a
multifaceted molecule in terms of buﬀering capacity. At
pH values lower than 4.6 all of the amino groups in the
spermine are protonated, while at pH=8o n l yt w oa r e
purportedly ionized, which promotes arrangement into a
lamellar structure [48]. The packing ability of DOGS is due,
inpart,tothedynamicsofthelargeheadgroupmoleculeand
the length of long unsaturated carbon chains.
3.3. Modiﬁcations for Improved Liposome-Mediated
Gene Delivery
3.3.1. Poly(ethylene) Glycol. Recent improvements in lipo-
fection have facilitated protection from degradation in
vivo, due to surface modiﬁcations with polyethylene glycol
(PEG). PEG presents many attractive qualities as a liposomal
coating, such as availability in a variety of molecular weights,
lack of toxicity, ready excretion by the kidneys, and ease of
application [49]. Methods of modifying liposomal surfaces
with PEG include its physical adsorption onto the liposomal
surface and its covalent attachment onto premade liposomes
[50].
It has been shown by Kim et al. [51] that PEGylated
lipoplexes yield increased transfection eﬃciencies in the
presence of serum as compared to liposomal transfection
methods lacking such surface attachments. Additionally, theJournal of Drug Delivery 7
PEGylated lipoplexes display improved stabilities and longer
circulation times in the blood. It is thought that the PEG
forms a steric barrier around the lipoplexes, which stiﬂes
clearance due to reduced macrophage uptake [50], and
may allow the liposome to overcome aggregation problems
through mutually repulsive interactions between the PEG
molecules [52]. These characteristics increase bioavailability,
facilitating higher transfection eﬃciencies due to improved
tissue distribution and larger available concentrations [53].
Because of the decreased immune responses and
increased circulation times associated with PEG-modiﬁed
liposomes, these particles are sometimes referred to as
“stealth liposomes.” However, such liposomes lack speciﬁcity
with regard to cellular targeting. Notably, Shi et al. found
that PEGylation inhibited endocytosis of the lipoplexes in
a fashion that was dependent upon the mole percentage
of PEG on the liposome, as well as the identity of certain
functional groups that were conjugated to the lipoplexes
[54]. Additionally, upon incorporation into the cell, PEG
worked to deter proper complex dissociation by stabilizing a
lamellar phase of DNA packing. As a result of these ﬁndings,
a need has arisen for the creation of novel PEG-containing
liposomes whereby the attached PEG is removed following
endocytosis via a hydrolysable connecting molecule.
3.3.2. Additions and Alternatives to Poly(ethylene) Glycol.
Alternative liposomal formulations utilizing polymers other
than PEG are being produced with the goal of creating ster-
ically protected lipoplexes. Additional aims of such systems
include biocompatibility, ﬂexible structure, and solubility in
physiological systems [50]. A report by Metselaar et al. on
the use of L-amino-acid-based polymers for lipoplex mod-
iﬁcation found an extended circulation time and reduced
clearance by macrophages at levels similar to those seen
with lipoplexes modiﬁed with PEG. Results suggested that
approximately 10% of the injected dose of the L-amino-
acid-modiﬁed complexes was still present in the blood of
treated rats after 48 hours [49]. These oligopeptides are
attractive alternatives to PEG due to advantages such as
increased biodegradability and favorable pharmacokinetics
when lower concentrations are used per dose.
Liposomes can also be coupled to targeting moieties
through the use of PEG to impart attraction to aﬀected
tissues for optimal routing and transfection. Targeting
ligands are selected based upon speciﬁc target cell receptors.
The target cells can be normal or transformed (tumor) cells.
Examples of such ligands include transferrin [55], a popular
ligand for delivery of anticancer drugs to solid tumors in
vivo,andhaloperidol[56],aligandthatassociateswithsigma
receptors that are overexpressed in many types of cancer.
4. Neutral Lipids
4.1. DOPE and DOPC (see Figure 8). Most liposomal for-
mulations used for gene delivery consist of a combination
of charged lipids and neutral helper lipids [12, 22–24, 26,
28]. The neutral helper lipids used are often dioleoylphos-
phatidylethanolamine (DOPE), which is the most widely
used neutral helper lipid, or dioleoylphosphatidylcholine
(DOPC). Results have shown that the use of DOPE ver-
sus DOPC as the helper lipid yields higher transfection
eﬃciencies in many cell types [28, 57], thought to be
due to a conformational shift to an inverted hexagonal
packing structure (Figure 2) that is imparted by DOPE
at low pH. In contrast to the creation of repeated layers
of DNA/lipids, as is the case in lamellar packing, the
inverted hexagonal packing structure is similar to that of
a honeycomb of tubular structures which condense DNA
inside the tubes through electrostatic interactions. The tubes
aggregate due to Van der Waals interactions between the
lipid tails that spread out to encircle each tube. Fusion
and destabilization of the lipoplexes during transfection are
thought to occur due to the exposure of the endosomal
membrane to invasive hydrocarbon chains [58]. Studies
have suggested that a hexagonal conformation allows for
eﬃcient escape of complexed DNA from endosomal vesicles
via destabilization of the vesicle membrane [17, 59]. With
the lysosomotropic agent chloroquine inhibiting the activity
of DOPE-containing lipoplexes, it is reasonable to assume
that the membrane-destabilizing hexagonal conformation
associated with DOPE is brought about at acidic pH [26].
In DOTAP-mediated DNA-binding studies, it was
discovered that liposomes—formulated without DOPE—
wouldnot eﬀectivelycomplexwithDNAtoneutralizeituntil
a 2:1 N:P ratio was reached due to an inability to displace
counter ions bound to the cationic lipid head groups [41].
In contrast, complexes with a 1:1 ratio of DOTAP/DOPE
continuously neutralized and complexed with the negatively
charged DNA at all charge ratios. This is possibly due
to salt bridges more easily forming between the positively
charged head groups of the cationic lipids and the phosphate
groups of DOPE moieties. This association would force the
primary amine of DOPE to stabilize itself in the plane of
the liposome surface and allow for more close interactions
with the negatively charged phosphate of the DNA. DOPE
could also facilitate counter ion release from the positively
charged lipid head group, thus lowering the energy required
for binding DNA [41]. Circular dichroism has been used to
indicate that the use of DOPE as a helper lipid allows for
much closer contact and packing of DNA helices [41].
DC-Chol and other cholesterol derivatives have been
incorporated into lipoplex assembly for increased transfec-
tion eﬃciency in vivo [60, 61]. Galactosylated cholesterol
derivatives have been shown to lower cytotoxicity levels and
improve transfection eﬃciencies in human hepatoma cells
(Hep G2), likely due to the aﬃnity of cellular receptors
for galactosylated ligands [62]. This result indicates that
lipoplexes can be formulated for cell-speciﬁc uptake through
the addition of speciﬁc ligands.
5. AnionicLipids
In general, gene delivery by anionic lipids is not very eﬃ-
cient. The negatively charged head group prevents eﬃcient
DNA compaction due to repulsive electrostatic forces that
occur between the phosphate backbone of DNA and the
anionic head groups of the lipids. However, due to the fact8 Journal of Drug Delivery
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Figure 8: The structures of two neutral lipids. (a) DOPE (b) DOPC.
that cationic liposomes can be inactivated in the presence
of serum, are unstable upon storage, and exhibit some
cytotoxicity both in vitro and in vivo, anionic liposomes
have been studied as potential gene delivery vehicles [63–
65]. Formation of DNA-containing liposomes using anionic
lipids can be brought about through the use of divalent
cations to negate the mutual electrostatic repulsion and
facilitate lipoplex assembly [8]. Anionic lipoplexes are com-
posed of physiologically safe components including anionic
lipids, cations, and plasmid DNA [66]. Commonly used
lipids in this category are phospholipids that can be found
naturally in cellular membranes such as phosphatidic acid,
phosphatidylglycerol, and phosphatidylserine (Figure 9). As
with the lipids presented earlier, anionic lipids can contain
any of a wide range of fatty acid chains in the hydrophobic
region. The speciﬁc fatty acids incorporated are responsible
for the ﬂuidic characteristics of the liposome in terms of
phase behavior and elasticity [2]. Perhaps due to the natural
presence of these speciﬁc phospholipids in the host cell
membrane, gene delivery via lipoplexes with net negative
surface potentials has been associated with lower clearance
and phagocytosis by macrophages, which is consistent with
favorable biocompatibility [67].
Various anionic liposomes have been characterized for
gene delivery in a small number of cell types including
CHO cells and primary hippocampal neurons [8, 66, 68,
69]. While such investigations are novel, overall knowledge
regarding anionic lipofection is as yet limited due to a lack
of extensive testing; DNA entrapment in anionic liposomes
is still ineﬃcient, and cytotoxicity data remain inadequate.
Divalent cations can be incorporated into the system to
enable the condensation of nucleic acids prior to envelop-
ment by anionic lipids. Several divalent cations have been
testedforuseinanioniclipoplexessuchasCa2+,Mg 2+,Mn 2+,
and Ba2+, but it has been observed that the use of Ca2+
yielded the highest transfection eﬃciency due to its higher
DNA binding aﬃnity [70, 71]. An investigation conducted
by Srinivasan and Burgess conﬁrmed that Ca2+ was the
most eﬀective cation for DNA compaction as compared to
Na+ and Mg2+ [66]. This aﬃnity is potentially a result of
the smaller hydrodynamic radius of calcium which gives a
larger charge per unit surface area. The use of Ca2+ not only
overcamethestrongelectrostaticrepulsionbetweentheDNA
and the lipids, but also promoted uptake of the lipoplexes
by the cell [8]. However, the use of high concentrations of
calcium (in excess of 25mM) was shown to be detrimental
to transfection eﬃciency because of the creation of aggregate
lipoplexes, having particle sizes of 500nm and higher [66].
Optimum transfection eﬃciency is achieved with particles
sizes of about 200nm due to factors thought to be related
to clathrin-mediated uptake [72].
Mixtures of the anionic lipid dioleoylphosphatidylglyc-
erol (DOPG) and the neutral lipid DOPE have been
investigated to determine an optimal ratio for transfectionJournal of Drug Delivery 9
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Figure 9: Anionic Lipids. (a) Phosphatidic acid (pH = 7). (b)
Phosphatidylglycerol. (c) Phosphatidylserine.
[66]. It was suggested that a 1:4 ratio of DOPG to
DOPE was a proper balance to allow the negatively charged
phospholipidstoformlipoplexeswhilestillhavingenoughof
the neutrally charged phospholipids to allow for endosomal
escape. DOPG has a packing parameter less than 1 and tends
to form ﬂexible bilayers and vesicles (Figure 2)[ 73]. This
characteristic can be contrasted to that of DOPE, which has a
packing parameter greater than one and is known to adopt
an inverted hexagonal structure that promotes membrane
destabilization [13, 70]. Transmission electron microscopy
revealed that this particular formulation yields liposomes
of a spherical multilamellar structure [66]. However, upon
relocation to the late endosome or endolysosome, the
lipoplex may alter its morphology due to the eﬀects of pH
upon the DOPE. The 1 : 4 ratio was seen to exhibit higher
transfection eﬃciency and cell viability versus the cationic
formulation Lipofectamine 2000 [66].
Despite some favorable investigations into the use of
anionic liposomes for gene delivery, there are some potential
downfalls associated with systemic delivery that must be
further explored. Some studies have indicated that, upon
exposure to certain plasma lipoproteins, destabilization and
leakage of liposomal contents can occur. For example, in
liposomes lacking cholesterol, high density lipoprotein can
cause some disintegration of the liposome [74]. However,
in liposomes which do contain cholesterol, low density
lipoproteins can also cause leakage of contents [75]. Char-
acterization studies like these are very useful in terms of
determining what mole percentages and types of lipids must
be taken away or added to liposomal formulations to obtain
maximum delivery of a desired cargo.
6. Concluding Remarks
An abundance of uses for liposomes has been investigated
since their introduction into the scientiﬁc literature in the
1960s. These studies have highlighted both the self-assembly
of various lipid formulations and dynamic properties of cel-
lular membranes as they interact with the local environment.
Not only have mechanisms of membrane transport and
pharmaceuticalcargodeliveryvialiposomesbeenelucidated,
but analytical uses such as immunoassays and biosensors
have also been developed.
At the rudimentary level, most lipids that self assemble
into useful shapes are amphipathic, containing both a
hydrophilic head group and a hydrophobic lipid tail group.
The shapes that are formed are determined by the types
of lipids used, which, in turn, provide various options
regarding delivery. The cationic head groups appear to be
better suited for DNA delivery due to the natural charge
attraction between negatively charged phosphate groups and
the positively charged head groups. Anionic head groups are
perhaps better suited for drug delivery. However, this does
not preclude their use as gene delivery vehicles as work with
divalent cations has shown.
One must keep in mind all of the variables that come
into play when using diﬀerent gene delivery vectors. There
is no concrete comparison that can easily be made to suggest
that one liposomal vector is better than another for all cell
types, environments, and applications. While some of the
lipids presented above were originally found to yield little-
to-no cytotoxicity for a given cell type, the observation
does not necessarily hold true when they are applied to
diﬀerent cell types [23–25]. Improvements and adjustments
to these formulations are constantly being explored through
the addition of diﬀerent lipids, targeting molecules, or
shielding moieties designed to prevent clearance in vivo.T h e
identiﬁcation of the optimal gene delivery vector continues
to be an elusive process, and liposomes are but a fraction of
all the vehicles that are being examined.
References
[1] A. D. Bangham, M. M. Standish, and J. C. Watkins, “Diﬀusion
of univalent ions across the lamellae of swollen phospho-
lipids,”JournalofMolecularBiology,vol.13,no.1,pp.238–252,
1965.
[2] A. Jesorka and O. Orwar, “Liposomes: technologies and ana-
lytical applications,” Annual Review of Analytical Chemistry,
vol. 1, no. 1, pp. 801–832, 2008.
[3] P. R. Leduc, M. S. Wong, P. M. Ferreira et al., “Towards an in
vivo biologically inspired nanofactory,” Nature Nanotechnol-
ogy, vol. 2, no. 1, pp. 3–7, 2007.
[4] T. Montier, T. Benvegnu, P.-A. Jaﬀr` es, J.-J. Yaouanc, and P.
Lehn, “Progress in cationic lipid-mediated gene transfection:
a series of bioinspired lipids as an example,” Current Gene
Therapy, vol. 8, no. 5, pp. 296–312, 2008.10 Journal of Drug Delivery
[5] C. Tros de Ilarduya, Y. Sun, and N. D¨ uzg¨ unes ¸, “Gene
delivery by lipoplexes and polyplexes,” European Journal of
Pharmaceutical Sciences, vol. 40, no. 3, pp. 159–170, 2010.
[6] I. Koltover, T. Salditt, and C. R. Saﬁnya, “Phase diagram,
stability, and overcharging of lamellar cationic lipid- DNA
self-assembled complexes,” Biophysical Journal, vol. 77, no. 2,
pp. 915–924, 1999.
[7] G. Gregoriadis, Liposome Technology,T a y l o r&
Francis/Informa, New York, NY, USA, 2006.
[8] S.D.Patil,D.G.Rhodes,andD.J.Burgess,“Anionicliposomal
delivery system for DNA transfection,” The AAPS Journal, vol.
6, no. 4, article no. e29, 2004.
[9] D.-G. Margineanu, “Equilibrium and non-equilibrium
approaches in biomembrane thermodynamics,” Archives
Internationales de Physiologie et de Biochimie,v o l .9 5 ,n o .5 ,
pp. 381–422, 1987.
[10] S. Svetina and B. Zeks, “Shape behavior of lipid vesicles as the
basis of some cellular processes,” Anatomical Record, vol. 268,
no. 3, pp. 215–225, 2002.
[11] M. Shimomura and T. Sawadaishi, “Bottom-up strategy of
materials fabrication: a new trend in nanotechnology of soft
materials,” Current Opinion in Colloid and Interface Science,
vol. 6, no. 1, pp. 11–16, 2001.
[12] P. P. Karmali and A. Chaudhuri, “Cationic liposomes as
non-viral carriers of gene medicines: resolved issues, open
questions, and future promises,” Medicinal Research Reviews,
vol. 27, no. 5, pp. 696–722, 2007.
[13] J. N. Israelachvili, Intermolecular and Surface Forces,A c a d e m i c
Press, London, UK, 2nd edition, 1991.
[14] E. Mayhew and D. Papajadjopoulos, “Therapeutic applica-
tions of liposomes,” in Liposomes, M. J. Ostro, Ed., pp. 289–
341, Marcel Dekker, New York, NY, USA, 1983.
[15] D. Lasic, Liposomes: From Physics to Applications,E l s e v i e r ,
Amsterdam, The Netherlands, 1993.
[16] B. Sternberg, “New structures in complex formation between
DNA and cationic liposomes visualized by freeze-fracture
electron microscopy,” FEBS Letters, vol. 356, no. 2-3, pp. 361–
366, 1994.
[17] I. Koltover, T. Salditt, J. O. R¨ adler, and C. R. Saﬁnya,
“An inverted hexagonal phase of cationic liposome-DNA
complexes related to DNA release and delivery,” Science, vol.
281, no. 5373, pp. 78–81, 1998.
[18] J.O.R¨ adler,I.Koltover,T.Salditt,andC.R.Saﬁnya,“Structure
of DNA-cationic liposome complexes: DNA intercalation
in multilamellar membranes in distinct interhelical packing
regimes,” Science, vol. 275, no. 5301, pp. 810–814, 1997.
[19] J. Gustafsson, G. Arvidson, G. Karlsson, and M. Almgren,
“Complexes between cationic liposomes and DNA visualized
by cryo-TEM,” Biochimica et Biophysica Acta, vol. 1235, no. 2,
pp. 305–312, 1995.
[20] W.-L. Hsu, H.-L. Chen, W. Liou, H.-K. Lin, and W.-L. Liu,
“Mesomorphic complexes of DNA with the mixtures of a
cationic surfactant and a neutral lipid,” Langmuir, vol. 21, no.
21, pp. 9426–9431, 2005.
[21] L. Wasungu and D. Hoekstra, “Cationic lipids, lipoplexes and
intracellular delivery of genes,” Journal of Controlled Release,
vol. 116, no. 2, pp. 255–264, 2006.
[22] P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a
highly eﬃcient, lipid-mediated DNA-transfection procedure,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 84, no. 21, pp. 7413–7417, 1987.
[23] R. Leventis and J. R. Silvius, “Interactions of mammalian cells
with lipid dispersions containing novel metabolizable cationic
amphiphiles,” Biochimica et Biophysica Acta, vol. 1023, no. 1,
pp. 124–132, 1990.
[24] X. Gao and L. Huang, “A novel cationic liposome reagent for
eﬃcient transfection of mammalian cells,” Biochemical and
Biophysical Research Communications, vol. 179, no. 1, pp. 280–
285, 1991.
[25] J.-P. Behr, B. Demeneix, J.-P. Loeﬄer, and J. Perez-Mutul,
“Eﬃcient gene transfer into mammalian primary endocrine
cells with lipopolyamine-coated DNA,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 86, no. 18, pp. 6982–6986, 1989.
[26] H. Farhood, N. Serbina, and L. Huang, “The role of dioleoyl
phosphatidylethanolamine in cationic liposome mediated
gene transfer,” Biochimica et Biophysica Acta, vol. 1235, no. 2,
pp. 289–295, 1995.
[27] J.-P. Behr, “Gene transfer with synthetic cationic amphiphiles:
prospects for gene therapy,” Bioconjugate Chemistry,vol. 5, no.
5, pp. 382–389, 1994.
[28] H. Farhood, X. Gao, K. Son et al., “Cationic liposomes for
direct gene transfer in therapy of cancer and other diseases,”
Annals of the New York Academy of Sciences, vol. 716, pp. 23–
35, 1994.
[29] A. Kikuchi, Y. Aoki, S. Sugaya et al., “Development of novel
cationic liposomes for eﬃcient gene transfer into peritoneal
disseminated tumor,” Human Gene Therapy,v o l .1 0 ,n o .6 ,p p .
947–955, 1999.
[ 3 0 ]C .J .W h e e l e r ,P .L .F e l g n e r ,Y .J .T s a ie ta l . ,“ An o v e lc a t i o n i c
lipidgreatlyenhancesplasmidDNAdeliveryandexpressionin
mouselung,”ProceedingsoftheNationalAcademyofSciencesof
the United States of America, vol. 93, no. 21, pp. 11454–11459,
1996.
[31] V. Budker, V. Gurevich, J. E. Hagstrom, F. Bortzov, and J.
A. Wolﬀ, “pH-sensitive, cationic liposomes: a new synthetic
virus-likevector,”NatureBiotechnology,vol.14,no.6,pp.760–
764, 1996.
[32] N. Maurer, A. Mori, L. Palmer et al., “Lipid-based systems
for the intracellular delivery of genetic drugs,” Molecular
Membrane Biology, vol. 16, no. 1, pp. 129–140, 1999.
[33] A. Elouahabi and J.-M. Ruysschaert, “Formation and intra-
cellular traﬃcking of lipoplexes and polyplexes,” Molecular
Therapy, vol. 11, no. 3, pp. 336–347, 2005.
[34] P. Pires, S. Sim˜ oes, S. Nir, R. Gaspar, N. D¨ uzg¨ unes, and M. C.
Pedroso De Lima, “Interaction of cationic liposomes and their
DNA complexes with monocytic leukemia cells,” Biochimica et
Biophysica Acta, vol. 1418, no. 1, pp. 71–84, 1999.
[35] M. E. Ferrari, D. Rusalov, J. Enas, and C. J. Wheeler,
“Synergy between cationic lipid and co-lipid determines the
macroscopic structure and transfection activity of lipoplexes,”
Nucleic Acids Research, vol. 30, no. 8, pp. 1808–1816, 2002.
[36] J.-S. Remy, C. Sirlin, P. Vierling, and J.-P. Behr, “Gene
transfer with a series of lipophilic DNA-binding molecules,”
Bioconjugate Chemistry, vol. 5, no. 6, pp. 647–654, 1994.
[37] E. Uchida, H. Mizuguchi, A. Ishii-Watabe, and T. Hayakawa,
“Comparison of the eﬃciency and safety of non-viral vector-
mediated gene transfer into a wide range of human cells,”
Biological and Pharmaceutical Bulletin, vol. 25, no. 7, pp. 891–
897, 2002.
[38] R. W. Malone, P. L. Felgner, and I. M. Verma, “Cationic
liposome-mediated RNA transfection,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 86, no. 16, pp. 6077–6081, 1989.
[39] T. Ren, Y. K. Song, G. Zhang, and D. Liu, “Structural basis
of DOTMA for its high intravenous transfection activity in
mouse,” Gene Therapy, vol. 7, no. 9, pp. 764–768, 2000.Journal of Drug Delivery 11
[40] J. H. Felgner, R. Kumar, C. N. Sridhar et al., “Enhanced gene
delivery and mechanism studies with a novel series of cationic
lipid formulations,” Journal of Biological Chemistry, vol. 269,
no. 4, pp. 2550–2561, 1994.
[41] N. J. Zuidam and Y. Barenholz, “Electrostatic and structural
properties of complexes involving plasmid DNA and cationic
lipids commonly used for gene delivery,” Biochimica et
Biophysica Acta, vol. 1368, no. 1, pp. 115–128, 1998.
[42] J. Zabner, A. J. Fasbender, T. Moninger, K. A. Poellinger, and
M. J. Welsh, “Cellular and molecular barriers to gene transfer
by a cationic lipid,” Journal of Biological Chemistry, vol. 270,
no. 32, pp. 18997–19007, 1995.
[43] J.-P. Yang and L. Huang, “Time-dependent maturation of
cationic liposome-DNA complex for serum resistance,” Gene
Therapy, vol. 5, no. 3, pp. 380–387, 1998.
[44] C. Marchini, M. Montani, A. Amici et al., “Structural stability
and increase in size rationalize the eﬃciency of lipoplexes in
serum,” Langmuir, vol. 25, no. 5, pp. 3013–3021, 2009.
[45] N. J. Zuidam and Y. Barenholz, “Electrostatic parameters
of cationic liposomes commonly used for gene delivery as
determined by 4-heptadecyl-7-hydroxycoumarin,” Biochimica
et Biophysica Acta, vol. 1329, no. 2, pp. 211–222, 1997.
[46] P. S. Ajmani and J. A. Hughes, “3β [N-(NM ,N  -
dimethylaminoethane)-carbamoyl] cholesterol (DC-chol)-
mediated gene delivery to primary rat neurons: characteriza-
tion and mechanism,” Neurochemical Research, vol. 24, no. 5,
pp. 699–703, 1999.
[47] S. Jain, G. Zon, and M. Sundaralingam, “Base only binding
of spermine in the deep groove of the A-DNA octamer
d(GTGTACAC),” Biochemistry, vol. 28, no. 6, pp. 2360–2364,
1989.
[48] T. Boukhnikachvili, O. Aguerre-Chariol, M. Airiau, S. Lesieur,
M. Ollivon, and J. Vacus, “Structure of in-serum transfecting
DNA-cationic lipid complexes,” FEBS Letters, vol. 409, no. 2,
pp. 188–194, 1997.
[49] J. M. Metselaar, P. Bruin, L. W. T. De Boer et al., “A
novel family of L-amino acid-based biodegradable polymer-
lipid conjugates for the development of long-circulating
liposomeswitheﬀectivedrug-targetingcapacity,”Bioconjugate
Chemistry, vol. 14, no. 6, pp. 1156–1164, 2003.
[50] M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes:
review of the basic science, rationale, and clinical applications,
existing and potential,” International Journal of Nanomedicine,
vol. 1, no. 3, pp. 297–315, 2006.
[51] J.-K. Kim, S.-H. Choi, C.-O. Kim, J.-S. Park, W.-S. Ahn,
and C.-K. Kim, “Enhancement of polyethylene glycol (PEG)-
modiﬁed cationic liposome-mediated gene deliveries: eﬀects
on serum stability and transfection eﬃciency,” Journal of
PharmacyandPharmacology,vol.55,no.4,pp.453–460,2003.
[52] D. Needham, T. J. McIntosh, and D. D. Lasic, “Repulsive
interactions and mechanical stability of polymer-grafted lipid
membranes,” Biochimica et Biophysica Acta, vol. 1108, no. 1,
pp. 40–48, 1992.
[53] M. DeCastro, Y. Saijoh, and G. C. Schoenwolf, “Optimized
cationic lipid-based gene delivery reagents for use in devel-
oping vertebrate embryos,” Developmental Dynamics, vol. 235,
no. 8, pp. 2210–2219, 2006.
[54] F. Shi, L. Wasungu, A. Nomden et al., “Interference of
poly(ethylene glycol)-lipid analogues with cationic-lipid-
mediated delivery of oligonucleotides; role of lipid exchange-
ability and non-lamellar transitions,” Biochemical Journal, vol.
366, no. 1, pp. 333–341, 2002.
[55] O.Ishida,K.Maruyama,H.Tanahashietal.,“Liposomesbear-
ing polyethyleneglycol-coupled transferrin with intracellular
targetingpropertytothesolidtumorsinvivo,” Pharmaceutical
Research, vol. 18, no. 7, pp. 1042–1048, 2001.
[56] A. Mukherjee, T. K. Prasad, N. M. Rao, and R. Banerjee,
“Haloperidol-associated stealth liposomes: a potent carrier
for delivering genes to human breast cancer cells,” Journal of
Biological Chemistry, vol. 280, no. 16, pp. 15619–15627, 2005.
[57] S. Sim˜ oes, V. Slepushkin, R. Caspar, M. C. Pedroso de Lima,
and N. D¨ uzg¨ unes ¸ ,“ G e n ed e l i v e r yb yn e g a t i v e l yc h a r g e d
ternary complexes of DNA, cationic liposomes and transferrin
orfusigenicpeptides,”GeneTherapy,vol.5,no.7,pp.955–964,
1998.
[58] S. Chesnoy and L. Huang, “Structure and function of lipid-
D N Ac o m p l e x e sf o rg e n ed e l i v e r y , ”Annual Review of Bio-
physics and Biomolecular Structure, vol. 29, pp. 27–47, 2000.
[59] I. S. Zuhorn, U. Bakowsky, E. Polushkin et al., “Nonbilayer
phase of lipoplex-membrane mixture determines endosomal
escape of genetic cargo and transfection eﬃciency,” Molecular
Therapy, vol. 11, no. 5, pp. 801–810, 2005.
[60] M. J. Bennett, M. H. Nantz, R. P. Balasubramaniam, D. C.
Gruenert, and R. W. Malone, “Cholesterol enhances cationic
liposome-mediated DNA transfection of human respiratory
epithelial cells,” Bioscience Reports, vol. 15, no. 1, pp. 47–53,
1995.
[61] K. Hong, W. Zheng, A. Baker, and D. Papahadjopoulos,
“Stabilization of cationic liposome-plasmid DNA complexes
by polyamines and poly(ethylene glycol)-phospholipid conju-
gates for eﬃcient in vivo gene delivery,” FEBS Letters, vol. 400,
no. 2, pp. 233–237, 1997.
[62] S.Kawakami,F.Yamashita,M.Nishikawa,Y.Takakura,andM.
Hashida, “Asialoglycoprotein receptor-mediated gene transfer
using novel galactosylated cationic liposomes,” Biochemical
and Biophysical Research Communications, vol. 252, no. 1, pp.
78–83, 1998.
[ 6 3 ]J .M a r s h a l l ,N .S .Y e w ,S .J .E a s t m a n ,C .J i a n g ,R .K .S c h e u l e ,
andS.H.Cheng,“Cationiclipid-mediatedgenedeliverytothe
airways,” in Nonviral Vectors for Gene Therapy,L .H u a n g ,M . -
C. Hung, and E. Wagner, Eds., pp. 39–68, Academic Press, San
Diego, Calif, USA, 1999.
[64] K. Lappalainen, I. Jaaskelainen, K. Syrjanen, A. Urtti, and S.
Syrjanen, “Comparison of cell proliferation and toxicity assays
using two cationic liposomes,” Pharmaceutical Research, vol.
11, no. 8, pp. 1127–1131, 1994.
[65] S.Dokka,D.Toledo,X.Shi,V.Castranova,andY.Rojanasakul,
“Oxygen radical-mediated pulmonary toxicity induced by
some cationic liposomes,” Pharmaceutical Research, vol. 17,
no. 5, pp. 521–525, 2000.
[66] C. Srinivasan and D. J. Burgess, “Optimization and charac-
terization of anionic lipoplexes for gene delivery,” Journal of
Controlled Release, vol. 136, no. 1, pp. 62–70, 2009.
[67] F. Roerdink, N. M. Wassef, E. C. Richardson, and C. R. Alving,
“Eﬀects of negatively charged lipids on phagocytosis of lipo-
somes opsonized by complement,” Biochimica et Biophysica
Acta, vol. 734, no. 1, pp. 33–39, 1983.
[68] A. Lakkaraju, J. M. Dubinsky, W. C. Low, and Y.-E. Rahman,
“Neurons are protected from excitotoxic death by p53 anti-
senseoligonucleotidesdeliveredinanionicliposomes,”Journal
of Biological Chemistry, vol. 276, no. 34, pp. 32000–32007,
2001.
[69] S. D. Patil, D. G. Rhodes, and D. J. Burgess, “Biophysical char-
acterization of anionic lipoplexes,” Biochimica et Biophysica
Acta, vol. 1711, no. 1, pp. 1–11, 2005.
[70] D. D. Lasic and N. S. Templeton, “Liposomes in gene therapy,”
Advanced Drug Delivery Reviews, vol. 20, no. 2-3, pp. 221–266,
1996.12 Journal of Drug Delivery
[71] V. I. Kulkarni, V. S. Shenoy, S. S. Dodiya, T. H. Rajyaguru,
a n dR .R .M u r t h y ,“ R o l eo fc a l c i u mi ng e n ed e l i v e r y , ”Expert
Opinion on Drug Delivery, vol. 3, no. 2, pp. 235–245, 2006.
[72] J. Rejman, V. Oberle, I. S. Zuhorn, and D. Hoekstra,
“Size-dependent internalization of particles via the pathways
of clathrin-and caveolae-mediated endocytosis,” Biochemical
Journal, vol. 377, no. 1, pp. 159–169, 2004.
[73] R. Koynova and R. C. MacDonald, “Natural lipid extracts and
biomembrane-mimicking lipid compositions are disposed
to form nonlamellar phases, and they release DNA from
lipoplexes most eﬃciently,” Biochimica et Biophysica Acta, vol.
1768, no. 10, pp. 2373–2382, 2007.
[74] G.Scherphof,F.Roerdink,M.Waite,andJ.Parks,“Disintegra-
tion of phosphatidylcholine liposomes in plasma as a result
of interaction with high-density lipoproteins,” Biochimica et
Biophysica Acta, vol. 542, no. 2, pp. 296–307, 1978.
[75] S. J. Comiskey and T. D. Heath, “Serum-induced leakage of
negatively charged liposomes at nanomolar lipid concentra-
tions,” Biochemistry, vol. 29, no. 15, pp. 3626–3631, 1990.